Driving Transformative Change for Better Health

Alberta Boehringer Ingelheim Collaboration Fund

In partnership with Boehringer Ingelheim (Canada) Ltd., the University Hospital Foundation and the Government of Alberta, the Collaborative is a public-private philanthropic partnership created to focus on developing solutions to address treatment gaps in the area of Chronic Obstructive Pulmonary Disease (COPD) care and its associated co-morbidities including diabetes, obesity and heart failure.

The partnership has three objectives:

Prevention of progression of patients with COPD

Management of COPD related co-morbidities (diabetes and heart failure) and keeping patients in their communities

Improve COPD for patients within Alberta’s vulnerable populations and design innovations to address these health challenges

ABIC 2019 Competition Winners

Michael K. Stickland, PhD

Dr. Michael Stickland, Professor in the Pulmonary Division, Faculty of Medicine and Dentistry at the University of Alberta, Director of the G. F. MacDonald Centre for Lung Health, Scientific Director for the Alberta Health Services Respiratory Strategic Clinical Network

  • Breathe Easy Pulmonary Rehabilitation: Scale, Spread and Sustain – Pulmonary rehabilitation is a multidisciplinary ambulatory intervention that includes assessment, exercise training, self-management education, and psychosocial support. The project will provide pulmonary rehabilitation program resources to patients/families and health care professionals in order to improve shortness of breath, exercise tolerance and quality of life in patients with COPD, with the potential of reducing the consequent increase in acute care demand for this population.

Heather Sharpe

RN, PhD, CRE, CTE, Assistant Scientific Director of the Respiratory Health Strategic Clinical Network (RHSCN), Adjunct Assistant Professor at the University of Calgary, Cumming School of Medicine, Department of Medicine

  • Identifying Early COPD Using Health Administrative Data – The project will use health administrative date to find out if we can identify trends in health care use by individuals newly diagnosed with COPD, in order to find new ways to identify patients at the early stages of their disease, since COPD often goes undiagnosed, so that preventative treatment can be initiated. This has the potential to improve quality of life and delay the need for prolonged hospitalizations and frequent emergency department visits.
“We are proud to support these innovative projects to improve the outcome of patients with chronic diseases such as COPD,” says Uli Brödl, Vice President, Medical and Regulatory Affairs, Boehringer Ingelheim (Canada) Ltd. “Patients are at the heart of everything we do, and we are dedicated to developing novel solutions that drive transformative change for a better patient experience.”
“By connecting the support of our generous community members to public-private philanthropic partnerships like the ABIC Fund, we are able to have a greater impact on healthcare innovation,” says Christy Holtby, Vice President, Strategic Partnerships with the University Hospital Foundation. “The fund recipients are tackling serious health issues and have the possibility of pioneering innovative solutions that will improve the lives of patients. The University Hospital Foundation is so grateful for the ongoing support from community members to help fund this forward-thinking collaboration.”
“We are pleased to support Alberta-based innovation and industry-driven applied research projects in respiratory diseases, says Tanya Fir, Minister of Economic Development, Trade and Tourism with the Government of Alberta. Not only do these projects advance patient care and research for Albertans, they also highlight the many opportunities that exist in the province to attract investment from health multinational enterprises.”

COPD is expected to be the 3rd leading cause of death by 2030.


Boehringer Ingelheim has over 95 years of heritage in treating respiratory disease


Over 2 million Canadians are living with COPD

News & Announcements

ABICfund First


Alberta Boehringer Ingelheim Collaboration aims to tackle care gaps in respiratory diseases



Alberta Boehringer Ingelheim Collaboration Fund announces new research for patients living with respiratory disease

About the Partners

Boehringer Ingelheim (Canada) Ltd.

Family-owned since it was established in 1885, Boehringer Ingelheim is one of the top 20 companies in the pharmaceutical industry. Some 50,000 employees create value through innovation daily for the three business areas of human pharmaceuticals, animal health and biopharmaceuticals. In 2018, Boehringer Ingelheim achieved net sales of around 17.5 billion euros. R&D expenditure of almost 3.2 billion euros, corresponded to 18.1 per cent of net sales.

As a family-owned company, Boehringer Ingelheim plans in generations and focuses on long-term success. The company therefore aims at organic growth from its own resources with simultaneous openness to partnerships and strategic alliances in research. In everything it does, Boehringer Ingelheim naturally adopts responsibility towards mankind and the environment.

More information about Boehringer Ingelheim can be found on their website.

University Hospital Foundation

Through donor support, the University Hospital Foundation provides funding that allows our medical teams at the University of Alberta Hospitals to remain on the forefront of medical advancements, keeping pace with constantly changing technology, emerging patient needs, and the latest knowledge and research discoveries.

Christy Holtby
Vice President, Strategic Partnerships

Ministry of Economic Development, Trade and Tourism

The Ministry of Alberta Economic Development, Trade and Tourism focuses on economic growth and diversification by supporting innovation and research; expanding access to capital for small and medium-sized enterprises; promoting trade, investment and market access initiatives; and leading Alberta’s negotiations on trade agreements.

University Hospital Foundation

Phone: 780-407-7007
Fax: 780-407-6603

Charitable Registration Number: 88900-3240 RR0001